ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment

CompletedOBSERVATIONAL
Enrollment

11

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

December 30, 2022

Study Completion Date

December 30, 2022

Conditions
Immune Related Adverse EventsColitisHepatitisDermatitis
Interventions
DRUG

ECP

Treatment with ECP for irAEs with 2 cycles performed on two consecutive days, for the first 4 weeks repeated every week, and from week 5 to 12 repeated every two weeks

Trial Locations (1)

79106

Medical Center - University of Freiburg Albert-Ludwigs-University Freiburg Department of Medicine I, Freiburg im Breisgau

All Listed Sponsors
lead

University of Freiburg

OTHER